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Objectives
Although the benefits of adopting test-and-treat antiretroviral therapy (ART) guidelines that
recommend initiation of ART regardless of CD4 cell counts have been demonstrated at the
individual level, there is uncertainty about how this translates to the population level. Here, we
explored whether adopting ART guidelines recommending earlier treatment initiation improves
population ART access and viral suppression and reduces overall disease transmission.
Methods
Data on ART initiation guidelines and treatment coverage, viral suppression, and HIV incidence
from 37 European and Central Asian countries were collected from the European Centre for
Disease Prevention and Control and the Global HIV Policy Watch and HIV 90-90-90 Watch
databases. We used multivariate linear regression models to quantify the association of ART
initiation guidelines with population ART access, viral suppression, and HIV incidence, adjusting
for potential confounding factors.
Results
Test-and-treat policies were associated with 15.2 percentage points (pp) [95% confidence interval (CI)
0.8–29.6 pp; P = 0.039] greater treatment coverage (proportion of HIV-positive people on ART)
compared with countries with ART initiation at CD4 cell counts ≤ 350 cells/lL. The presence of test-and-
treat policies was associated with 15.8 pp (95% CI 2.4–29.1 pp; P = 0.023) higher viral suppression rates
(people on ART virally suppressed) compared with countries with treatment initiation at CD4 counts
≤ 350 cells/lL. ART initiation at CD4 counts ≤ 500 cells/lL did not significantly improve ART coverage
compared to initiation at CD4 counts ≤ 350 cells/lL but achieved similar degrees of viral suppression as
test-and-treat.
Conclusions
Test-and-treat was found to be associated with substantial improvements in population-level
access to ART and viral suppression, further strengthening evidence that rapid initiation of
treatment will help curb the spread of HIV.
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Introduction
In 2015, the World Health Organization (WHO) and the
European AIDS Clinical Society called for universal test-
and-treat programmes, with initiation of antiretroviral ther-
apy (ART) immediately upon diagnosis of HIV infection, as
a means to reduce rates of HIV-related illness and mortality
and onward transmission [1–3]. The rationale for reducing
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onward transmission derived primarily from evidence that
early treatment reduced the risk of mother-to-child trans-
mission and in serodiscordant couples [4–16]. The HIV Pre-
vention Trials Network (HPTN052) trial had found that ART
initiation at CD4 counts of between 350 and 550 cells/lL
led to a reduction of 96% in HIV transmission compared to
delaying ART initiation until the CD4 count was ≤ 250
cells/lL [12,16]. This was consistent with earlier observa-
tional studies and supported by systematic reviews
[11,13,14,17]. Yet, the argument that this would lead to
population-level benefits was controversial. Some argued
that expanding ART might create a false sense of security
among those affected, perversely encouraging greater rates
of unsafe sex [18–20], which has been contested [21–24].
Others highlighted constraints to scaling up treatment as a
result of limited resources, especially in low-income settings
[25–27], uncertainty about the use of data from clinical tri-
als that showed ‘modest benefits’ [28], nonreplicability at
the community level [29,30], and the risk of increasing rates
of adverse effects caused by ART and resistance [26,31].
In Europe, a key argument centred on whether findings
in couples could be generalized to the wider population,
especially as the incidence was lower than in other parts of
the world and, in many European countries, was declining.
This reflected the limited evidence at the population level,
with studies producing mixed findings but often suggest-
ing that population-level benefits may be more modest
than those found in trials at the individual level. A number
of ecological studies have been carried out, but mostly in
single communities. An association between greater ART
coverage and lower viral loads and transmission has been
reported in diverse settings, including British Columbia in
Canada [32–34], San Francisco in the USA [35], KwaZulu-
Natal in South Africa [17,36], and Taiwan [37]. One cross-
national study found that expanding ART coverage in the
30 highest AIDS mortality burden countries correlated with
reduced mortality rates from HIV-related causes [38]. How-
ever, a recent review argued that findings from existing
population-level studies were mixed, with one study
reporting decreasing risk per contact among those on ART
being counteracted by more unsafe sexual episodes [18].
Another review found that test-and-treat appeared to be
less effective at the population level than anticipated from
modelling studies [29,30].
Here, we take advantage of a unique opportunity to test
the impact of the expansion of test-and-treat policies in 37
European and Central Asian countries. Several countries
pre-empted the adoption of the test-and-treat guidelines in
WHO’s 2015 recommendations, while others have yet to
change (see Table S1). These marked differences in timing
enabled us to test the hypothesis that expanding test-and-
treat guidelines increases population access to ART cover-
age and, in so doing, improves viral suppression and
reduces HIV incidence (as described in Fig. 1).
Methods
Data sources
We collected data on the prevalence of HIV-positive status,
the proportion of people diagnosed with HIV infection with
access to ART, and proportion of people on ART with viral
suppression from the European Centre for Disease Prevention
and Control (ECDC)’s HIV Treatment and Care and Contin-
uum of HIV Care reports covering 37 countries in the WHO
European Region [39,40]. This includes the European Union
and European Economic Area (EU/EEA) (24 countries) as well
as Eastern European and Central Asian countries (13 coun-
tries). ECDC’s system for monitoring progress against the
Dublin Declaration on Partnership to Fight HIV/AIDS has
been described elsewhere [39–42]; briefly, ECDC surveys
health ministries and other health authorities for data on
access to ART and viral suppression. The years for which data
are available vary across countries between 2012 and 2016,
with most (26 countries) providing data for the year 2015.
Table S2 lists all 37 countries included in the analyses and
details the year of available data for each country. The data
sources also varied across countries [39]. For instance, for the
number of people with HIV infection who are on ART, 29%
of countries used surveillance data, 26% used cohort data,
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Fig. 1 Conceptual framework of the relationship between antiretroviral therapy (ART) initiation policies, ART coverage and viral suppression.
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and 45% used another data source. For reporting the number
of people who are virally suppressed, 26% of countries used
surveillance data, 44% used cohort data, and 30% used
another data source. Table S3 provides detailed information
of the data source used in each country.
The European Centre for Disease Prevention and Control
has produced definitions to harmonize reporting practices
[41]. Current ART status is based on persons using ART, irre-
spective of treatment regimen or treatment interruptions
and discontinuations. Viral suppression is defined as having
initiated treatment and achieved a viral load ≤ 200 HIV-1
RNA copies/mL of blood at the last attendance for HIV care.
Nonetheless, countries employed slightly varying definitions
for reporting data on ART prevalence and viral suppression,
introducing measurement errors [41–43]. Data on access to
ART and viral suppression in Kazakhstan and Kyrgyzstan
only included patients who were ≥ 15 years old.
Data on new HIV infection rates per 100 000 population
were obtained for all countries from The European Surveil-
lance System (TESSy) to which countries provide surveil-
lance data, as reported by ECDC and the WHO Regional
Office for Europe [44]. To capture changes in HIV transmis-
sion, we calculated the growth rate as the difference
between the rate in the year for which each country had
available data on the other variables (ART access and viral
suppression) and the rate in the previous year. However,
these data have limits in capturing reduced HIV transmis-
sion, as newly reported HIV diagnoses include recently
infected individuals as well as those who were infected sev-
eral years ago but only recently tested for HIV [44].
Data on ART guidelines in the year for which the data
were available were taken from the ECDC Dublin Declara-
tion monitoring and country reports [40,45,46], the Global
HIV Policy Watch database (June 2017 edition) [47], and
the HIV 90-90-90 Watch database (May 2017 edition) [48].
Table S1 summarizes the ART policies that countries had in
place in the year for which the HIV data were available.
Where discrepancies occurred, we used the more compre-
hensive HIV Policy Watch database. Guidelines were cate-
gorized into three groups: those recommending ART
initiation at CD4 cell counts ≤ 350 cells/lL, ART initiation
at CD4 counts ≤ 500 cells/lL, and universal treatment (i.e.
test-and-treat or treatment initiation irrespective of CD4
count). No country in the sample used the 2003 WHO HIV
treatment guidelines recommending treatment initiation at
CD4 counts ≤ 200 cells/lL.
Statistical modelling
To adjust for potential confounding factors, we used mul-
tivariate linear regression models, corresponding to the
causal chain outlined in Figure 1:
Prevalence of HIV-positive persons with ART accessi
¼ a þ b1 ART guidelinesi þ b2 log GDPi
þ b3 public health expenditurei
þ b4 HIV prevalencei þ b5 region þ ei
Here, i is country, GDP is gross domestic product per
capita and e is the error term. ART guideline is coded as
an ordinal variable, as described above. Log GDP per cap-
ita is in international constant 2011 purchasing power
parity-adjusted US dollars to facilitate cross-national
comparisons and adjust for positive skew. To address the
possibility that wealthier nations may achieve greater
access, we also adjusted for public health expenditures
per capita in international constant 2011 US dollars
adjusted for purchasing power parity and inflation. We
also included additional adjustments for country HIV
burden and region (EU/EEA or Eastern Europe and Cen-
tral Asia). Data on the number of people with HIV infec-
tion were taken from ECDC [39] and data on the total
population were taken from the World Bank World
Development Indicators (WDI) database to calculate HIV
prevalence. All other data on control variables were taken
from the World Bank WDI database for the year 2015,
corresponding to the year in which most countries
reported HIV data, except for public health expenditures,
which were from 2014, the latest year in which all coun-
tries provided data [49].
In the second step, we quantified the association
between ART initiation policy and viral suppression, per-
forming a mediation analysis, as follows:
Prevalence of HIV-positive persons with viral
suppressioni ¼ a þ b1 ART guidelinesi þ b2 log GDPi
þ b3 public health expenditurei
þ b4 HIV prevalencei þ b5 region þ ei
Finally, we investigated the association between ART
initiation guidelines and the growth rate of new HIV
infections per 100 000 population as a proxy for change
in transmissibility:
Growth rate of HIV incidence per 100 000i
¼ a þ b1 ART guidelinesi þ b2 log GDPi
þ b3 public health expenditurei
þ b4 HIV prevalencei þ b5 region þ ei
To account for potential heteroscedasticity, robust stan-
dard errors were used. In view of the small sample size
and potential overfitting, we present for both models,
first, unadjusted, more parsimonious results, and, sec-
ondly, fully specific models adjusted for several controls.
All models were estimated using STATA, version 13.0 (Sta-
taCorp, College Station, TX).
© 2019 The Authors.
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Results
Impact of test-and-treat guidelines on population-
level ART access among people with diagnosed HIV
infection
An estimated 1.2 million people were living with HIV,
of whom 0.7 million were receiving ART (< 60%). In
the EU/EEA (24 countries), 77.5% of the people diag-
nosed with HIV infection were on ART and, of those,
86.6% had attained viral suppression. These estimates,
respectively, were lower, at 57.1% and 59.8%, in Eastern
Europe and Central Asia (13 countries). Table S4
describes the HIV data obtained from the 37 countries
in the sample.
At the time the data were published, in April 2017, 14
of the 37 countries had yet to adopt test-and-treat guide-
lines, which corresponds to about 25% of the population
in the 37 countries not covered by universal HIV treat-
ment. We observed that seven countries (all from EU/
EEA) began test-and-treat prior to the WHO 2015 guide-
line update, corresponding to about 20% of the countries
included in the sample and covering 35% of the popula-
tion in the sample countries. Of the 14 countries that
have not updated their guidelines to the latest (2015)
WHO and EACS recommendations at the time the data
were published in 2017, 11 (29.7% of the countries and
about 21% of the total population in the sample coun-
tries) had guidelines recommending treatment at CD4 cell
counts ≤ 500 cells/lL, corresponding to the WHO guideli-
nes of 2013. The guidelines of three countries (Azerbai-
jan, Lithuania and Tajikistan; 8.1% of the countries and
4% of the sample population) recommend initiation of
ART at CD4 cell counts ≤ 350 cells/lL, corresponding to
the 2010 WHO guidelines. Of the 14 countries that have
not adopted test-and-treat, four countries are from the
EU/EEA: Belgium, Bulgaria and Luxemburg (CD4 count
≤ 500 cells/lL), and Lithuania (CD4 count ≤ 350 cells/
lL). Table S3 summarizes the state of the ART policies
for the studied countries.
Figure 2a (panel 1) shows the proportion of people on
ART out of all people living with diagnosed HIV infection
by country. Unadjusted, test-and-treat policies achieve
greater access to ART (mean 82.4%), compared with
policies that employ CD4 threshold restrictions
(mean 60.1%). Countries with test-and-treat policies had,
on average, 22.3 percentage points more diagnosed HIV-
positive people on ART (two-tailed t-test: t = 4.03;
P = 0.0003). As shown in Figure 2b, an increase in access
to ART appeared to occur most often when moving from
any CD4 restriction to test-and-treat, rather than from
the threshold of CD4 count ≤ 350 cells/lL to CD4 count
≤ 500 cells/lL. Table S2 describes the ART initiation
guidelines in the year data were available in each of the
countries shown in Figure 2a.
Table 1 shows the results of our multivariate linear
regression model quantifying the association of test-and-
treat with population-level access to ART among people
with diagnosed HIV infection. Countries that had test-and-
treat policies had a 20.8 (95% CI 5.2–36.4; P = 0.01) per-
centage points increase of people on ART compared with
countries with guidelines recommending treatment initia-
tion at CD4 counts ≤ 350 cells/lL. After controlling for the
level of economic development, HIV prevalence, subregion
and public health care expenditure, the estimated effect
size was attenuated to 15.2 percentage points (95% CI 0.8–
29.6; P = 0.039), appearing to reflect mainly how better
resourced and wealthier health systems also achieved
higher rates of uptake.
Impact of test-and-treat on population-level viral
suppression among people on ART
Figure 3 depicts the positive unadjusted association
between the percentage of people diagnosed with HIV
infection who were on ART and the percentage of people
diagnosed with HIV who were on ART with viral suppres-
sion (r = 0.57; P = 0.001). It shows that countries with
higher ART coverage were more likely to achieve a
higher percentage of population-level viral suppression
among people on ART.
As shown in the unadjusted plots in Figure 4a (panel 2),
we observed that test-and-treat policies were associated
with a higher proportion of population-level viral suppres-
sion among HIV-positive patients on ART (mean 86.1%)
compared with countries with CD4 restrictions for ART ini-
tiation (mean 67.9%). Countries with ART policies offering
treatment for all had, on average, 18.1 percentage points
more viral suppression among patients on ART compared
with countries restricting treatment only to patients with
low CD4 cell counts; this difference was significant at the
5% level (two-sample t-test: t = 2.91; P < 0.007). Fig-
ure 4b shows a steady increase in the average percentage
of people on ART with viral suppression as the inclusive-
ness of the three ART initiation policies increased,
whereby, in countries with the most inclusive treatment
guidelines, i.e. test-and-treat, the populations achieved the
highest levels of viral suppression.
After adjusting for potential confounders in a multivari-
ate linear regression model, as shown in Table 2, we found
that test-and-treat was associated with 15.8 percentage
points more of people on ART achieving viral suppression
compared with countries with treatment initiation at CD4
© 2019 The Authors.
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counts ≤ 350 cells/lL (95% CI 2.4–29.1%; P = 0.007).
Countries with guidelines recommending initiation of ART
at CD4 cell counts ≤ 500 cells/lL achieved similar levels
of viral suppression to countries with test-and-treat poli-
cies (15.1 percentage points; 95% CI 1.2–29.1; P = 0.023).
Impact of test-and-treat on HIV transmission
Table 3 shows the results of our multivariate linear
regression model quantifying the association of ART ini-
tiation guidelines and the growth rate of new HIV infec-
tions per 100 000 population. We found that, after
adjusting for potential confounders, countries with ART
initiation at CD4 cell counts ≤ 500 cells/lL had an asso-
ciated 16% reduction in their new HIV infection rates per
100 000, compared with countries with ART initiation at
CD4 cell counts ≤ 350 cells/lL (95% CI 30 to 1.4%;
P = 0.033). No difference was observed between countries
with test-and-treat ART guidelines and countries with
ART initiation at CD4 cell counts ≤ 350 cells/lL (6.3%;
95% CI 23.5 to 10.9%; P = 0.46).
Robustness check
As country-years of data availability varied, we also
included a variable for the year of data availability to
Fig. 2 Population-level access to antiretroviral therapy (ART) and ART initiation guidelines. (a) Percentage of people diagnosed with HIV infection on
ART by country and average percentage by ART initiation policy. (b) Percentage of people diagnosed with HIV infection on ART by ART initiation policy.
© 2019 The Authors.
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adjust for the potential effect of secular trends. None of
the results was qualitatively unchanged.
Discussion
We found a significant association between adoption of
test-and-treat guidelines and greater access to both
ART and viral suppression compared with the use of a
CD4 count ≤ 350 cells/lL threshold, even after adjust-
ing for potential confounding factors. While we found
that test-and-treat was associated with greater access to
ART when compared with the most restrictive ART ini-
tiation policy (CD4 counts ≤ 350 cells/lL), there were
no statistically significant differences between ART ini-
tiation at CD4 counts ≤ 500 cells/lL and at CD4 counts
≤ 350 cells/lL. This indicates that the effect of test-
and-treat on expanding ART coverage is probably sub-
stantial in comparison with any alternative ART initia-
tion policy. We also found that greater viral
suppression was achieved with both test-and-treat and
ART initiation at CD4 counts ≤ 500 cells/lL compared
with ART initiation at CD4 counts ≤ 350 cells/lL,
which is important given that this is associated with
reduced HIV-related illness, deaths, and transmissibility
[35,50]. Community viral load has been proposed as an
effective population-level biomarker of HIV burden and
as a novel means of assessing the potential impact of
Table 1 Association of antiretroviral therapy (ART) initiation guide-
lines with population-level access to ART among people diagnosed
with HIV infection
Percentage of people diagnosed with HIV
infection on ART
Model 1 Model 2
ART initiation guidelines
Initiation at CD4 count
≤ 350 cells/lL
Reference Reference
Initiation at CD4 count
≤ 500 cells/lL
2.65
(19.1 to 13.8)
0.23
(13.3 to 13.8)
Initiation at any CD4
count (test-and-treat)
20.8* (5.20–36.4) 15.2* (0.82–29.6)
Per 1% increase in GDP per
capita ($927)
1.58 (7.89 to 11.1)
Per $1000 increase in
health care expenditure
per capita
6.55* (1.61–11.5)
Per 1 SD increase in HIV
prevalence (SD = 0.17%)
4.77 (10.6 to 1.03)
Region
EU/EEA Reference
Eastern Europe and
Central Asia
3.04 (14.7 to 20.8)
Number of countries 37 37
R2 0.319 0.626
A constant was included in all models but is not shown. 95% confi-
dence intervals are shown in brackets. Model 1: unadjusted; model 2:
adjusted for level of economic development, HIV prevalence, subregion
and public health care expenditure.
EU/EEA, European Union and European Economic Area; SD, standard
deviation.
*P < 0.05.
Fig. 3 Association between the percentage of people diagnosed with HIV infection on antiretroviral therapy (ART) and the percentage of
people on ART with viral suppression.
© 2019 The Authors.
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population-level HIV prevention and treatment inter-
ventions [50]. When we studied the association between
ART initiation policy and per cent change in new HIV
infection rates, we observed that earlier treatment initi-
ation at CD4 counts ≤ 500 cells/lL was associated with
a decline in new HIV infections but initiation irrespec-
tive of CD4 cell count was not associated with a
decline when compared with initiation at CD4 counts
≤ 350 cells/lL.
Our findings are consistent with those of other studies.
First, the association between test-and-treat and higher
ART coverage is both intuitive and consistent with the
findings of other studies showing earlier initiation of ART
to be associated with increased ART coverage [51,52].
Secondly, the association between test-and-treat and
greater population-level viral suppression among people
on ART is also consistent with the results of several stud-
ies that reported that increased ART coverage and earlier
initiation of ART were linked to improved HIV outcomes
[32–34,36–38,52–55], including attainment of viral sup-
pression [35,50,56,57] and reduced transmission and inci-
dence [35,50]. Greater viral suppression of the population
under treatment initiation guidelines that recommend
therapy for all and for those with higher CD4 cell counts
(CD4 counts ≤ 500 cells/lL) might be explained by the
steady access to ART that confer these more inclusive
policies offering treatment to a greater proportion of the
HIV-positive population in contrast to an ART initiation
Fig. 4 Population-level viral suppression and antiretroviral therapy (ART) initiation guidelines. (a) Percentage of people on ART with viral suppres-
sion by country and average percentage by ART initiation policy. (b) Percentage of people on ART with viral suppression by ART initiation policy.
© 2019 The Authors.
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policy that delays treatment initiation until patients reach
lower CD4 cell counts.
The apparent effectiveness of test-and-treat in increas-
ing population-level ART coverage among people with
diagnosed HIV infection and increasing viral suppression
among people on ART reinforces the decision by some
countries, beginning in 2011, to adopt ART irrespective of
CD4 cell count and immediate initiation of ART with sim-
plified regimens; and it also reinforces the recommenda-
tions by the WHO and EACS in 2015 to adopt test-and-
treat policies as a contribution to achieving the UNAIDS
90-90-90 target. However, this will only be possible with
progress in the first stage in the HIV care cascade, the 90%
diagnosis target, as even a small number of undiagnosed
people could sustain an epidemic [58]. Also, other stages
of the HIV care continuum not directly measured in the
90-90-90 scheme are important to reach the UNAIDS tar-
get, such as linking diagnosed HIV-positive patients to
services and ensuring sustained and appropriate care, like
switching to second-line therapy regimens when necessary
[27]. Indeed, we found increased access to ART and viral
suppression in stronger health systems, which are likely to
provide better retention within the system because of
increased availability, accessibility and affordability of
services. Thus, achieving the 90-90-90 target will require
both HIV-specific measures, such as test-and-treat policies
and universal access to ART, and also general improve-
ments to the health system.
There are some limitations to this study. The first is
the risk of ecological fallacy. While exposure to a given
ART initiation guideline is a national policy that should
apply to everyone, we cannot exclude the possibility
that some populations subject to stigma and discrimina-
tion might be treated differently. For instance, only
about half of the countries in Europe and Central Asia
offer HIV treatment to undocumented migrants [59].
Other populations that are also likely to suffer differen-
tial provision of HIV health care services are sex work-
ers [60,61] and people who inject drugs [62,63].
Consequently, our results are likely to be conservative
estimates of the association between ART initiation poli-
cies and population-level access to ART. A second,
linked, limitation is the assumption that adoption of the
guidelines translated into implementation. If failure to
implement guideline recommendations was randomly
distributed across various ART initiation policies, this
would have yielded conservative estimates. Nonrandom
variation would have yielded biased estimates. However,
many countries adopted the guidelines some time before
Table 2 Association of antiretroviral therapy (ART) initiation guide-
lines with population-level viral suppression among people on ART
Percentage of people on ART with viral
suppression
Model 1 Model 2
ART initiation guidelines
Initiation at CD4 count ≤ 350
cells/lL
Reference Reference
Initiation at CD4 count ≤ 500
cells/lL
17.6 (4.06 to 39.3) 15.1* (1.18–29.0)
Initiation at any CD4 count
(test-and-treat)
26.9** (7.99–45.9) 15.8* (2.39–29.1)
Per 1% increase in GDP per
capita ($927)
9.95* (0.71–19.2)
Per $1000 increase in health care
expenditure per capita
1.66
(2.79 to 6.12)
Per 1 SD increase in HIV
prevalence (SD = 0.17%)
0.20
(4.99 to 5.38)
Region
EU/EEA Reference
Eastern Europe and Central
Asia
2.71
(21.4 to 16.0)
Number of countries 30 30
R2 0.335 0.648
A constant was included in all models but is not shown. 95% confi-
dence intervals are shown in brackets. Model 1: unadjusted; model 2:
adjusted for level of economic development, HIV prevalence, subregion
and public health care expenditure.
EU/EEA, European Union and European Economic Area; SD, standard
deviation.
*P < 0.05; **P < 0.01.
Table 3 Association of antiretroviral therapy (ART) initiation guide-
lines with the growth rate of new HIV infections per 100 000
population
Per cent change in new HIV
infection rate per 100 000
Model 1 Model 2
ART initiation guidelines
Initiation at CD4 count
≤ 350 cells/lL
Reference Reference
Initiation at CD4 count
≤ 500 cells/lL
17*
(0.30 to 0.043)
16*
(0.30 to 0.014)
Initiation at any CD4
count (test-and-treat)
8.2
(0.21 to 0.043)
6.3
(0.24 to 0.11)
Per 1% increase in GDP per
capita ($927)
0.031
(0.095 to 0.033)
Per $1000 increase in health
care expenditure per capita
0.00054
(0.044 to 0.043)
Per 1 SD increase in HIV
prevalence (SD = 0.17%)
0.025
(0.053 to 0.0036)
Region
EU/EEA Reference
Eastern Europe and
Central Asia
0.013
(0.18 to 0.16)
Number of countries 36 36
R2 0.217 0.262
A constant was included in all models but is not shown. 95% confi-
dence intervals are shown in brackets. Model 1: unadjusted; model 2:
adjusted for level of economic development, HIV prevalence, subregion
and public health care expenditure.
EU/EEA, European Union and European Economic Area; SD, standard
deviation.
*P < 0.05.
© 2019 The Authors.
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the reporting date and can be expected to have rolled
them out to ART services. Thirdly, there could be mea-
surement error in the outcome variables as a result of
different data collection procedures and misclassification
of outcome status, which could have biased our esti-
mates, diluting findings and making it harder to ascer-
tain an association. Indeed, some countries reported
very low levels of viral suppression; however, it is pos-
sible that these measurements were affected by different
factors, including treatment disruptions (voluntary or as
a result of stock-outs), use of first or second line of
treatment, loss to follow-up, transfer of care (people
moving to another clinic may show up as having been
lost to follow-up), out-migration, poor monitoring sys-
tems (tracking people and collecting data), and infre-
quent viral load measurements. A fourth limitation is
the small sample size used in the study, potentially
generating imprecise estimates of associations. However,
the finding of similar results in the larger sample,
notwithstanding the greater data problems, offers reas-
surance. A fifth limitation is that, of the 48 countries
that responded to the survey, 37 countries had data
available on ART coverage and 30 had data on viral
suppression of all people living with HIV [41,42]. Those
that either failed to respond or lacked data were mainly
from non-EU/EEA, Eastern European and Central Asian
countries that might have different characteristics from
the countries included in the analyses, which could
have biased our estimates. Sixthly, we used cross-sec-
tional data measuring exposure and outcome simultane-
ously. Reverse causality is a risk but is unlikely
because, while it is theoretically possible that a greater
proportion of people on ART and virally suppressed
could have exerted pressure for expanded ART initiation
policies, the association is much more likely to flow
from expanded ART initiation policies to a greater per-
centage of people on ART and virally suppressed.
Another limitation of cross-sectional data is that they
do not capture any lag effect between policy adoption
and treatment initiation. If there were lagged effects,
our estimates could be biased towards the null. Finally,
the country data used were drawn from different years,
reflecting the limitations of the country surveillance
and reporting systems; however, this did not affect our
ability to test our question across countries and years,
and as a robustness check the models were adjusted for
the year of data availability to account for the potential
effect of secular trends.
To our knowledge, this is the first ecological cross-
national analysis evaluating the impact of test-and-treat
on achievement of the 90-90-90 target internationally,
adjusting for several possible confounders. We offer
evidence of an association between test-and-treat guide-
lines and greater treatment coverage and viral suppres-
sion rates at the population level among people with
diagnosed HIV infection and on ART, respectively. While
it cannot be regarded as conclusive, it provides evidence
that must be assessed further using other research
designs, which could, for instance, include longitudinal
data for all countries. The cross-national character of
this study, including a broad variety of countries from
Europe and Central Asia, gives external validity to the
findings and the potential to generalize to other con-
texts.
Our results have important policy implications. First,
they support the recommendation of test-and-treat poli-
cies by the WHO and EACS as a means to achieve the
UNAIDS 90-90-90 target for 2020, which also align with
the Sustainable Development Goal target to end the HIV
epidemic by 2030. Secondly, they show that test-and-
treat policies can achieve results comparable to those that
might otherwise be expected with very large investments
in public health services. Thirdly, they reinforce the case
for intensification of efforts to expand new test-and-treat
policies in Eastern European and Central Asian countries.
However, our results do not provide guidance on how to
implement test-and-treat. A next step in research would
be to test empirically how to operationalize its implemen-
tation, along with the necessary services. Taken together,
our results are consistent with a growing body of
research indicating that test-and-treat is an effective
means to reducing the burden of disease attributable to
HIV.
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